Circassia Pharmaceuticals Plc Receives Innovative Tech Contract from Vizient
February 08 2018 - 2:00AM
RNS Non-Regulatory
TIDMCIR
Circassia Pharmaceuticals Plc
08 February 2018
Circassia Receives Innovative Technology Contract from Vizient,
Inc. for NIOX VERO(R) Asthma Management Products
Oxford, UK - 8 February 2018: Circassia Pharmaceuticals plc
("Circassia" or "the Company"; LSE: CIR), a specialty
pharmaceutical company focused on respiratory disease, today
announces that it has received a multi-year Innovative Technology
contract for its NIOX VERO(R) asthma management products from
Vizient, Inc., the largest member-owned health care company in the
United States. The contract was based on the recommendation of
hospital experts with expertise in this category who serve on one
of Vizient's member-led councils. Innovative Technology contracts
are reserved for technologies that demonstrate an ability to
enhance clinical care or patient safety, and those that improve an
organisation's care delivery and business model.
Circassia's NIOX VERO(R) products are used to assist asthma
diagnosis and management, and are indicated in the United States
for use in those aged 7 years and older. NIOX(R) is based on the
discovery that patients with Th2 or type 2 driven airway
inflammation, the major underlying cause of asthma, generally have
higher than normal levels of nitric oxide in their exhaled breath.
By measuring the concentration of this fractional exhaled nitric
oxide (FeNO), NIOX(R) enables clinicians to evaluate airway
inflammation in patients with underlying asthma, aiding diagnosis
and helping guide treatment and reduce exacerbations.
Steve Harris, Circassia's CEO, said: "Circassia is proud to be
awarded this prestigious Vizient Innovative Technology contract,
which recognises the important role NIOX VERO(R) plays in assisting
asthma diagnosis and management. Vizient is the largest
member-driven healthcare improvement company in the United States,
and its diverse membership and customer base includes academic
medical centres, paediatric facilities, community hospitals,
integrated health delivery networks and non-acute health care
providers with combined purchasing volume of approximately $100
billion annually. This new contract will provide Circassia with a
simplified route to access Vizient members as potential new
customers, helping us expand our number of accounts while offering
savings opportunities for NIOX(R) users."
Vizient, Inc. represents the combined strengths of the
organizations formerly known as VHA Inc., University HealthSystem
Consortium, Novation and MedAssets' Spend and Clinical Resource
Management. Since 2003, nearly 2,200 new and innovative products
and technologies have been submitted through the Vizient Innovative
Technology program. Vizient works with member-led councils and task
forces to identify and review potentially innovative products. If
it is determined that a product is innovative, a contract may be
awarded outside of Vizient's competitive bid cycle.
About Circassia
Circassia is a world-class specialty pharmaceutical business
focused on respiratory disease. Circassia sells its novel,
market-leading NIOX(R) asthma management products directly to
specialists in the United States, United Kingdom and Germany, and
in a wide range of other countries through its network of partners.
The Company recently established a collaboration with AstraZeneca
in the US in which it promotes the chronic obstructive pulmonary
disease (COPD) treatment Tudorza(R), and has the US commercial
rights to COPD product Duaklir(R).
Circassia's development pipeline includes a range of respiratory
medicines. The Company's lead asthma treatment targets substitution
of GSK's Flixotide(R) pMDI and was approved in the UK. Circassia is
also developing a direct substitute for Seretide(R) pMDI, and its
pipeline includes a number of inhaled medicines for COPD, including
single and combination dose products. For more information on
Circassia please visit www.circassia.com.
Contacts
Circassia
Steve Harris, Chief Executive Officer Tel: +44 (0) 1865 405
560
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
FTI Consulting
Simon Conway / Mo Noonan Tel: +44 (0) 20 3727 1000
Forward-looking statements
This press release contains certain projections and other
forward-looking statements with respect to the financial condition,
results of operations, businesses and prospects of Circassia. The
use of terms such as "may", "will", "should", "expect",
"anticipate", "project", "estimate", "intend", "continue", "target"
or "believe" and similar expressions (or the negatives thereof) are
generally intended to identify forward-looking statements. These
statements are based on current expectations and involve risk and
uncertainty because they relate to events and depend upon
circumstances that may or may not occur in the future. There are a
number of factors that could cause actual results or developments
to differ materially from those expressed or implied by these
forward-looking statements. Any of the assumptions underlying these
forward-looking statements could prove inaccurate or incorrect and
therefore any results contemplated in the forward-looking
statements may not actually be achieved. Nothing contained in this
press release should be construed as a profit forecast or profit
estimate. Investors or other recipients are cautioned not to place
undue reliance on any forward-looking statements contained herein.
Circassia undertakes no obligation to update or revise (publicly or
otherwise) any forward-looking statement, whether as a result of
new information, future events or other circumstances.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLGDDGBGBGIR
(END) Dow Jones Newswires
February 08, 2018 02:00 ET (07:00 GMT)
Circassia (LSE:CIR)
Historical Stock Chart
From Apr 2024 to May 2024
Circassia (LSE:CIR)
Historical Stock Chart
From May 2023 to May 2024